• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

Zero to Hero: How Creso Pharma Reignited its Future (ASX:CPH)

Like 0

By Lachlann Tierney, Monday, 01 February 2021

At time of writing, the share price of Creso Pharma Ltd [ASX:CPH] is up more than 10%, trading at 21.5 cents. Here’s the how the last five years played out for the CPH share price. From a high in late 2017, CPH was caught in a savage...

At time of writing, the share price of Creso Pharma Ltd [ASX:CPH] is up more than 10%, trading at 21.5 cents.

Here’s the how the last five years played out for the CPH share price:

ASX CPH Share Price Chart

Source: tradingview.com

From a high in late 2017, CPH was caught in a savage long-term downtrend until it levelled out in mid-2020.

A bout of sideways trading resulted in a big pop upwards in December.

We look at how CPH turned things around and what pushed the CPH share price higher today.

Announcement on CBD market builds excitement after initial surge

Here are the key points from today’s announcement:

  • ‘Low-dose CBD products can now be sold over-the-counter in Australian pharmacies as of today (1 Feb 2021)
  • Follows TGA’s decision to down schedule low-dose CBD products from Schedule 4 (Prescription Medicine) to Schedule 3 (Pharmacist Only)
  • Unlocks a market estimated to exceed $200m per annum1
  • Creso is well placed to capitalise through agreement with Martin & Pleasance which provides access to over 4,000 pharmacies across Australia
  • Collaboration with Martin & Pleasance progressing well, with both parties working to define regulatory pathways and business cases to grow Creso’s Australian footprint
  • Creso anticipated this legislation and regulatory approval and is in a strong position to capture the Australian Market
  • TGA regulatory approval is demonstrative of a growing global trend towards relaxation of legislation, making Creso products much more easily accessible to patients
  • Creso is also pre-empting further relaxations of cannabis regulations in other jurisdictions globally, including the US, and is advancing discussions with potential distribution and channel partners to position itself as a first mover in the US and other markets, at the appropriate time’

So another win for Creso, which wants to position itself as a leader in CBD products in Australia and elsewhere.

Outlook for CPH share price

A flurry of announcements combined with regulatory changes in a variety of jurisdictions. Having watched the company for a period of three years, it’s a remarkable turnaround.

From trading around 2.5 cents, it went as high as 47 cents in a short period of time before it subsequently fell back

I think the challenge for CPH will be to continue making progress on receipts from customers and capitalise on the regulatory changes that favour them.

I cover CPH in depth in the video below:


Regards,

Lachlann Tierney
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney

Lachlann’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • China’s plan to pop the AI bubble and sink Mag7 for good
    By Nick Hubble

    Back in January, China’s Artificial Intelligence program DeepSeek triggered a trillion-dollar meltdown in US AI stocks in a single day. What if this was just the beginning?

  • The latest Closing Bell is available now
    By Callum Newman

    Tune in today to watch the latest Closing Bell podcast with Murray Dawes. We discuss gold, the Alphabet (Google) outlook…and more!

  • Iron Ore Stocks: Opportunity if You Have a Strategy
    By James Cooper

    James Cooper digs into the potential iron ore opportunity, a commodity that could reward investors if they’re disciplined. Read on to find out one simple strategy you can apply in this sector.

Primary Sidebar

Latest Articles

  • China’s plan to pop the AI bubble and sink Mag7 for good
  • The latest Closing Bell is available now
  • Iron Ore Stocks: Opportunity if You Have a Strategy
  • Cash in thanks to billionaire Jim Rogers…NOW
  • Lies, Lies and GDP Statistics

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988